Navigation Links
Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market

WALTHAM, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Psoriasis finds that, among the TNF-alpha inhibitors, Amgen/Pfizer/Takeda's Enbrel maintained its market dominance in 2008 but Abbott/Eisai's Humira will emerge as the psoriasis market leader in 2018 with blockbuster sales of $1.3 billion. The report also finds that Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab -- both of which belong to the interleukin inhibitor drug class -- will together account for almost one-quarter of the psoriasis market in 2018. Briakinumab is the most promising emerging agent in the psoriasis market, according to the report.

"Briakinumab is expected to launch in early 2011 and we forecast that its sales will exceed $550 million in 2018," said Decision Resources Analyst Irene Koulinska, M.D. "In contrast, none of the oral agents in development such as Isotechnika Pharma's voclosporin and Celgene's apremilast seem to offer major advantages over marketed systemic therapies, and their potential launches are not expected to have a notable impact on the psoriasis market."

Incyte's Jak inhibitor INCB-18424, a topical therapy with a novel mechanism of action, is expected to receive regulatory approval in the United States and Europe in 2013. The report finds that although INCB-18424 has demonstrated excellent efficacy in Phase II clinical trials, safety concerns and competition from lower priced brand and generic corticosteroids and vitamin D3 analogues will restrict sales of the agent through 2018.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563

SOURCE Decision Resources

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan
2. New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements
3. Avid Bioservices Expands Executive Team as it Prepares for Continued Growth
4. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
5. Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide
6. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
7. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
8. DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth
9. On Third Anniversary, Compendia Bioscience Announces Continued Revenue Growth, Major Long-Term Customer Contracts and Forecasts Profitability
10. Nasdaq Panel Grants Advanced Life Sciences Request for Continued Listing on Nasdaq Stock Market
11. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
Post Your Comments:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):